Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Brand Name | Status | Last Update |
---|---|---|
frova | New Drug Application | 2018-08-27 |
frovatriptan | ANDA | 2024-12-12 |
frovatriptan succinate | ANDA | 2019-12-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
migraine disorders | EFO_0003821 | D008881 | G43 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 3 | 2 | 2 | 7 |
Headache | D006261 | — | R51 | — | — | 1 | 1 | — | 2 |
Premenstrual syndrome | D011293 | — | N94.3 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Metrorrhagia | D008796 | — | N92.1 | — | — | — | — | 1 | 1 |
Drug common name | Frovatriptan |
INN | frovatriptan |
Description | Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.
|
Classification | Small molecule |
Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1 |
PDB | — |
CAS-ID | 158747-02-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1279 |
ChEBI ID | — |
PubChem CID | 77992 |
DrugBank | DB00998 |
UNII ID | H82Q2D5WA7 (ChemIDplus, GSRS) |